What are the side effects of Caplyta (lumateperone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Caplyta Side Effects

The most common side effects of Caplyta (lumateperone) are sleepiness, dizziness, nausea, and dry mouth, with the medication demonstrating a favorable safety profile including minimal weight gain, metabolic changes, and extrapyramidal symptoms compared to other antipsychotics. 1

Most Common Side Effects (≥5% and twice placebo rate)

According to FDA labeling, the following side effects occur most frequently 1:

  • Sleepiness/somnolence
  • Dizziness
  • Nausea
  • Dry mouth
  • Fatigue
  • Diarrhea

Recent pooled analysis data confirms these findings, with treatment-emergent adverse events occurring in 68.1% of patients on lumateperone versus 45.1% on placebo. Importantly, 96.3% of adverse events were mild to moderate in severity 2.

Serious Side Effects Requiring Immediate Attention

Life-Threatening Risks

Neuroleptic Malignant Syndrome (NMS) - can be fatal. Seek emergency care immediately if you develop 1:

  • High fever
  • Confusion
  • Stiff muscles
  • Changes in breathing, heart rate, or blood pressure
  • Increased sweating

Stroke risk - increased in elderly patients with dementia-related psychosis (black box warning - Caplyta is NOT approved for this population) 1

Movement Disorders

Tardive dyskinesia - uncontrolled movements of face, tongue, or body parts that may be permanent even after stopping the medication 1. Real-world data shows tremor as the most common extrapyramidal symptom (3.9% vs 0.2% placebo), with mean duration of 11.9 days 2.

Metabolic and Cardiovascular Effects

Metabolic changes requiring monitoring 1:

  • High blood sugar/diabetes - check before starting and regularly during treatment
    • Warning signs: excessive thirst, frequent urination, extreme hunger, weakness, confusion, fruity breath
  • Elevated cholesterol and triglycerides - periodic monitoring needed
  • Weight gain - monitor regularly (though notably, only 0.4% experienced ≥7% weight increase versus 1.3% on placebo) 2

Orthostatic hypotension - lightheadedness or fainting when standing up quickly 1

Other Serious Risks

  • Low white blood cell count - blood tests needed in first few months 1
  • Seizures 1
  • Falls - due to sleepiness, dizziness, and orthostatic hypotension leading to fractures or injuries 1
  • Difficulty swallowing - can cause aspiration 1
  • Temperature regulation problems - feeling too warm 1
  • Fertility problems in both males and females 1

Discontinuation Rates

Treatment discontinuation due to adverse events occurred in 8.7% of patients on lumateperone versus only 0.8% on placebo 2. This higher discontinuation rate is a clinically important consideration despite the generally favorable tolerability profile.

Time Course of Adverse Events

Most adverse events occur within the first 10 days to 1 month after starting lumateperone, with median onset at 9 days 3.

Special Populations Warning

Increased suicidal thoughts and actions - particularly in children, adolescents, and young adults, especially within the first few months or when dose changes 1. Watch for new or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, aggression, suicidal thoughts, or unusual behavior changes.

Favorable Safety Profile Compared to Other Antipsychotics

Caplyta demonstrates placebo-level rates of 2, 4:

  • Weight gain (0.4% with ≥7% increase)
  • Metabolic disruption (minimal changes in cardiometabolic parameters)
  • Prolactin elevation (minimal changes)
  • Extrapyramidal symptoms excluding tremor

This positions lumateperone as having one of the most favorable metabolic and movement disorder profiles among atypical antipsychotics, which is particularly relevant for long-term morbidity and quality of life outcomes.

Related Questions

Does lumateperone (Caplyta) cause nausea and vomiting when taken with methadone, and what antipsychotic would be a better alternative?
What is an appropriate taper‑off schedule for an adult stable on Caplyta (lumateperone) 10.5 mg taken at bedtime?
Can I stop Caplyta (lumateperone) after only two weeks of treatment?
What are the contraindications for escitalopram (Lexapro), gabapentin, mirtazapine, atomoxetine (Strattera), and lumateperone (Caplyta)?
Can Trintellix (vortioxetine) be safely combined with Caplyta (lumateperone) in adult patients?
In a 54-year-old woman with bone fragility, arthritis‑like joint pain, tendon pathology, and pathologic fractures, are there any cancers that could contribute to this situation?
Is this hysterectomy pathology report appropriate and complete for a total hysterectomy with bilateral salpingo‑oophorectomy performed for International Federation of Gynecology and Obstetrics (FIGO) grade 1 endometrioid adenocarcinoma?
What is euvolemic hyponatremia?
What is the interpretation and recommended management for an arterial blood gas showing pH 7.38, PaCO₂ 58 mm Hg, PaO₂ 68 mm Hg, and elevated bicarbonate?
A patient has been on lamotrigine (Lamictal) 50 mg daily, increased to 75 mg daily two weeks ago; should the dose be increased to 100 mg or 125 mg?
In a patient with a history of congestive heart failure who has just started furosemide (Lasix) for bilateral lower extremity edema, should a fluid restriction be instituted automatically?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.